Riskpilot← Back to searchSign inGet full accessPharmaSite AB
ABActiveOrg 5567104434Föreningsgatan 26Research and experimental development on natural sciences and engineering · NACE 7210Est. 20062 employees
Revenue 2025
SEK 2,9M
-49% vs 2024
EBITDA margin
-15.7%
-186% vs 2024
Equity ratio
76.6%
Financial strength
Net profit 2025
SEK -748K
-240% vs 2024
| Revenue | SEK 2,9M | -49% |
| EBITDA | SEK -460K | -186% |
| Net profit | SEK -748K | -240% |
| Total assets | SEK 1,3M | -48% |
| Equity | SEK 982K | -43% |
| Employees | 2 | — |
Legal name
PharmaSite AB
Org number
5567104434
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
7 september 2006
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-05-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva sjukvård, kliniska läkemedelsprövningar, äga och förvalta fast och lös egendom samt därmed förenlig verksamhet.
Address
Föreningsgatan 26
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 176 | 1 176 | 3 091 | 5 711 | 2 932 |
| Staff expenses | — | −867 | — | — | — |
| EBITDA | −807 | −807 | −2 019 | 535 | −460 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −807 | −807 | −2 019 | 535 | −460 |
| Net financials | 11 912 | 11 912 | −7 | −1 | −658 |
| Profit before tax | 11 106 | 11 106 | −2 026 | 534 | −748 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 11 106 | 11 106 | −2 026 | 534 | −748 |
| Item | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 12 563 | 12 563 | 1 879 | 2 450 | 1 282 |
| Equity | 11 222 | 11 222 | 1 196 | 1 730 | 982 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 340 | 1 340 | 683 | 720 | 299 |
| Total debt | 1 340 | 1 340 | 683 | 720 | 299 |
EBITDA margin
-15.7%
This company
15.8%
Market median
-199% vs market
20222025
Equity ratio
76.6%
This company
38.2%
Market median
+101% vs market
20222025
Return on equity
-76.2%
This company
18.4%
Market median
-514% vs market
20222025
Net profit margin
-25.5%
This company
8.1%
Market median
-415% vs market
20222025
Asset turnover
2.29×
This company
1.12×
Market median
+104% vs market
20222025
Debt / equity
0.31×
This company
0.62×
Market median
+50% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-06-01 – 2025-05-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-06-01 – 2024-05-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-05-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-05-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JT | Audit | 2022 |
PT Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
P Koskinen Holding AB
PharmaSite AB Board members of PharmaSite AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jessica Thérése Wallin | Audit | 0 companies |
| Pekka Tapani Koskinen | Chief Executive Officer | 0 companies |
| My Sofia Alexandra Koskinen | Deputy Board Member | 0 companies |
| Max Henrik Koskinen | Deputy Board Member | 0 companies |